1. Home
  2. JOF vs STTK Comparison

JOF vs STTK Comparison

Compare JOF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Japan Smaller Capitalization Fund Inc

JOF

Japan Smaller Capitalization Fund Inc

HOLD

Current Price

$11.01

Market Cap

330.1M

Sector

Finance

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.42

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JOF
STTK
Founded
1990
2016
Country
Japan
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.1M
275.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
JOF
STTK
Price
$11.01
$6.42
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$7.60
AVG Volume (30 Days)
101.7K
691.5K
Earning Date
01-01-0001
04-30-2026
Dividend Yield
3.33%
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.43
$0.69
52 Week High
$12.76
$6.81

Technical Indicators

Market Signals
Indicator
JOF
STTK
Relative Strength Index (RSI) 48.38 67.18
Support Level $10.16 $5.75
Resistance Level $11.00 $6.81
Average True Range (ATR) 0.18 0.37
MACD 0.06 -0.04
Stochastic Oscillator 74.68 70.79

Price Performance

Historical Comparison
JOF
STTK

About JOF Japan Smaller Capitalization Fund Inc

Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: